AMPA receptor mediates mGlu 2/3 receptor antagonist-induced dopamine release in the rat nucleus accumbens shell

被引:15
作者
Karasawa, Jun-ichi [1 ]
Kotani, Makiko [1 ]
Kambe, Daiji [1 ]
Chaki, Shigeyuki [1 ]
机构
[1] Taisho Pharmaceut Co Ltd, Discovery Pharmacol Mol Funct & Pharmacol Labs, Kita Ku, Saitama 3319530, Japan
关键词
mGlu; 2/3; receptor; AMPA receptor; Microdialysis; Dopamine; Nucleus accumbens; LY341495; NBQX; CX546; METABOTROPIC GLUTAMATE-RECEPTOR; EXTRACELLULAR DOPAMINE; NMDA RECEPTORS; MESSENGER-RNA; ANTEROGRADE; PROJECTION; BEHAVIOR; MGS0039; COCAINE; BRAIN;
D O I
10.1016/j.neuint.2010.07.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The role of alpha-amino-3-hydroxy-5-methylisoxazole-4-ProPionate (AMPA) receptor activation in the regulation of dopamine release by the metabotropic glutamate (mGlu) 2/3 receptors in the nucleus accumbens (NAc) shell was investigated using an in vivo microdialysis evaluation. The local application of 101 mu M of LY341495, an mGlu 2/3 receptor antagonist, significantly increased extracellular dopamine levels in the NAc shell in freely moving rats. Pretreatment with an AMPA receptor antagonist, NBQX (0.3 mg/kg, i.p.) significantly attenuated the increase in dopamine release induced by LY341495 application to the basal level, while the systemic administration of NBQX alone had no effect on dopamine release in this region of the brain. Moreover, the local application of an AMPA receptor potentiator. CX546, at 100 or 3001 mu M also enhanced dopamine release in the NAc shell in a concentration-dependent manner. These findings suggest that the activation of the postsynaptic AMPA receptor plays a role in mediating the regulation of dopamine release by the mGlu 2/3 receptor in the NAc shell. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:615 / 619
页数:5
相关论文
共 31 条
[1]   Effects of cocaine on extracellular dopamine and serotonin levels in the nucleus accumbens [J].
Andrews, CM ;
Lucki, I .
PSYCHOPHARMACOLOGY, 2001, 155 (03) :221-229
[2]   Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data [J].
Black, MD .
PSYCHOPHARMACOLOGY, 2005, 179 (01) :154-163
[3]   THE ROLE OF ENDOGENOUS DOPAMINE IN THE HYPERMOTILITY RESPONSE TO INTRAACCUMBENS AMPA [J].
BOLDRY, RC ;
WILLINS, DL ;
WALLACE, LJ ;
URETSKY, NJ .
BRAIN RESEARCH, 1991, 559 (01) :100-108
[4]   THE PATTERNS OF AFFERENT INNERVATION OF THE CORE AND SHELL IN THE ACCUMBENS PART OF THE RAT VENTRAL STRIATUM - IMMUNOHISTOCHEMICAL DETECTION OF RETROGRADELY TRANSPORTED FLUOROGOLD [J].
BROG, JS ;
SALYAPONGSE, A ;
DEUTCH, AY ;
ZAHM, DS .
JOURNAL OF COMPARATIVE NEUROLOGY, 1993, 338 (02) :255-278
[5]   CHRONIC DESIPRAMINE ENHANCES THE EFFECT OF LOCALLY APPLIED AMPHETAMINE ON INTERSTITIAL CONCENTRATIONS OF DOPAMINE IN THE NUCLEUS-ACCUMBENS [J].
BROWN, EE ;
NOMIKOS, GG ;
WILSON, C ;
FIBIGER, HC .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 202 (01) :125-127
[6]   MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity [J].
Chaki, S ;
Yoshikawa, R ;
Hirota, S ;
Shimazaki, T ;
Maeda, M ;
Kawashima, N ;
Yoshimizu, T ;
Yasuhara, A ;
Sakagami, K ;
Okuyama, S ;
Nakanishi, S ;
Nakazato, A .
NEUROPHARMACOLOGY, 2004, 46 (04) :457-467
[7]   Group II metabotropic glutamate receptor-mediated regulation of dopamine release from slices of rat nucleus accumbens [J].
Chaki, Shigeyuki ;
Yoshikawa, Ryoko ;
Okuyama, Shigeru .
NEUROSCIENCE LETTERS, 2006, 404 (1-2) :182-186
[8]   Pharmacology and functions of metabotropic glutamate receptors [J].
Conn, PJ ;
Pin, JP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1997, 37 :205-237
[9]   Effects of agents targeting glutamatergic systems on marble-burying behavior [J].
Iijima, Michihiko ;
Kurosu, Shinsuke ;
Chaki, Shigeyuki .
NEUROSCIENCE LETTERS, 2010, 471 (02) :63-65
[10]   Role of AMPA and NMDA receptors in the nucleus accumbens shell in turning behaviour of rats: interaction with dopamine receptors [J].
Ikeda, H ;
Akiyama, G ;
Fujii, Y ;
Minowa, R ;
Koshikawa, N ;
Cools, AR .
NEUROPHARMACOLOGY, 2003, 44 (01) :81-87